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Objective. Based on case–control and prospective
studies elevated blood total homocysteine (tHcy)
has been suggested to be an independent risk
factor for cardiovascular diseases (CVD). The
purpose of the study was to explore the joint
effect of increased serum tHcy concentration and
other risk factors on the risk of CVD mortality in
middle-aged men without a history of heart
disease or stroke.
Design. A prospective, population-based Kuopio
Ischaemic Heart Disease Risk Factor (KIHD) Study.
Setting. Eastern Finland.
Subjects. A total of 802 men aged 46–64 years,
examined in 1991–93.
Main outcome measures. CVD mortality event.
Results. The mean serum tHcy concentration was
10.8 lmol L)1 (SD 3.3). During the average follow-
up time of 10.8 years 50 men experienced a CVD
death. The hazard rate ratio for CVD mortality was
1.80 (95% confidence interval: 1.02–3.19) in men
in the highest serum tHcy third versus lower thirds
after adjustment for cardiovascular risk factors.
Furthermore, elevated serum tHcy concentration
appeared to increase the risk of CVD death in men
who smoke or who have high circulating
concentrations of serum total or LDL cholesterol,
apo-B apolipoprotein or plasma fibrinogen.
Conclusion. We conclude that homocysteine may
increase the risk of CVD mortality in middle-aged men
from Eastern Finland, and it may especially increase
the risk when present with other risk factors for CVD.
Keywords: cardiovascular disease, homocysteine,
interaction, prospective studies, risk factors.
Introduction
Elevated blood levels of total homocysteine (tHcy), a
nonprotein-forming sulphur amino acid, have been
suggested to be an independent risk factor for
cardiovascular disease (CVD) [1]. Homocysteine is
derived from the metabolic demethylation of dietary
methionine. It can be either remethylated back to
methionine in a reaction which is catalysed by
methionine synthase with folate as the methyl donor
and vitamin B12 (cobalamin) as a cofactor or it can
be catabolized to cystathionine in a trans-sulfuration
pathway catalysed by cystathionine beta-synthase.
In this latter pathway vitamin B6 (pyridoxine) is an
essential cofactor.
Not all prospective studies have shown an associ-
ation between plasma/serum tHcy and risk of heart
disease. For example, in the Finnish prospective
studies looking at the effects of tHcy on the risk of
heart disease, elevated plasma tHcy concentrations
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have not been shown to increase the risk of CVD in
middle-aged men and women free of prior coronary
event [2–4]. However, the data on the effects of
increased blood tHcy concentrations on mortality
risk in subpopulations with CVD risk factors is
scarce. Hyperhomocysteinemia has been suggested
to contribute to the atherosclerotic processes in
similar ways as hypercholesterolaemia and high
plasma fibrinogen [1, 5, 6]. Therefore it can be
speculated that in subjects with these risk factors,
elevated blood tHcy may further increase the risk of
CVD. Furthermore, there is some previous data that
tHcy may be an independent risk factor in subjects
with increased serum total or LDL cholesterol or
plasma fibrinogen concentrations or who smoke
[7–11]. Thus, we wanted to test the hypothesis that
tHcy contributes to the risk of CVD death in middle-
aged men with increased serum total or LDL
cholesterol or plasma fibrinogen concentrations or
in men who smoke. The combined effect of tHcy and
serum apo-B was also investigated, as apo-B is one of
the lipoproteins of LDL and it has been found to be a
risk factor for CVD [12].
Materials and methods
Study population
The Kuopio Ischaemic Heart Disease Risk Factor
Study (KIHD) is an ongoing prospective population-
based cohort study designed to investigate risk
factors for CVD, atherosclerosis and related out-
comes in middle-aged men from eastern Finland
[13], the population with one of the highest recor-
ded rates of coronary heart disease (CHD). A total of
2682 participants (82.9% of eligible), aged 42, 48,
54, or 60 years, were enrolled in the study between
1984 and 1989. The study protocol was approved
by the Research Ethics Committee of the University
of Kuopio. All subjects gave their written informed
consent for participation. The baseline examinations
for the present analysis were carried out during
1991–93 at the 4-year re-examinations of the KIHD
study. Of the total of 1229 men eligible for the study,
52 had died, had had a severe illness, or had
migrated from the region, and 139 could not be
contacted or refused to participate. Thus, 1038 men
were examined in 1991–93. Men with a prevalent
CHD or stroke (n ¼ 225) were excluded from the
present analyses. Of the remaining 813 men, data
on serum tHcy concentrations were available for
802 men.
Determination of serum tHcy concentration
The subjects came to give venous blood samples
between 8 am and 10 am. They were instructed to
abstain from ingesting alcohol for 3 days and from
smoking and eating for 12 h prior to giving the
sample.
The serum tHcy concentration was analysed by
high-performance liquid chromatography in 2001
at the National Public Health Institute, Helsinki,
Finland, as described by Schwab et al. [14]. The
results represent total serum homocysteine, which is
referred as serum tHcy. The coefficient of variation
between batches (n ¼ 30) for two pooled serum
samples were 4.3% and 5.4%.
Other measurements
Assessment of medical history, smoking, alcohol
consumption and blood pressure was carried out as
described previously [15]. The collection of blood
specimens [15] and measurement of serum lipids
and lipoproteins [16] and plasma fibrinogen [17]
have been described in detail elsewhere. Body mass
index was computed as the ratio of weight in
kilograms to the square of height in metres.
Ascertainment of follow-up events
The CVD deaths were ascertained by a computer
linkage to the national death registry using the
Finnish personal identification code (social security
number). All CVD deaths that occurred from the
study entry to 31 December 2003 were included.
There were no losses to follow-up. CVD deaths were
coded according to the ICD-9 (International Classi-
fication of Diseases, Ninth Revision, code numbers
390–459) or the ICD-10 (code numbers I00–I99).
Statistical analysis
The data are expressed as mean ± SD. Mean values
were compared by analysis of variance (anova).
Correlations between serum tHcy and risk factors
studied were estimated with Pearson correlation
coefficients (r). The relationship of serum tHcy with
the risk of CVD mortality was analysed using Cox
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proportional hazards models. Risk factor-adjusted
hazard rate ratios (RR) were estimated as the
antilogarithms of coefficients from multivariable
models. Due to a limited number of cases only a
few covariates could be used without over-fitting the
models. The inclusion of covariates was based on a
change in RR of at least 10%. When this criterion
was used, smoking, systolic blood pressure and
serum LDL cholesterol in addition to age and
examination years remained in the models examin-
ing the effects of tHcy on the risk of CVD mortality in
the whole population. Only systolic blood pressure
remained as a covariate in addition to the age and
examination years in the models examining the
effects of tHcy with other risk factor. Interactions of
homocysteine with fibrinogen, total and LDL cho-
lesterol, apo-B and smoking were assessed by
stratified analyses and the use of a product term
with both risk factors as binary variables. Serum
tHcy level was categorized as low to moderate and
high according to the highest tertile
(>11.3 lmol L)1). Plasma fibrinogen, serum total
and LDL cholesterol and apo-B were categorized as
high or low according to the median value. Smoking
was categorized as yes/no. A subject was defined as
a smoker if he had ever smoked on a regular basis
and had smoked cigarettes, cigars, or a pipe within
the past 30 days. For the evaluation of joint effect,
four categories were generated: (i) neither risk factor
present, (ii) increased serum level of tHcy alone, (iii)
other risk factor alone, and (iv) increased serum
level of tHcy and other risk factor present. The
confidence intervals (CI) were estimated on the basis
of the assumption of asymptotic normality of the
estimates. All tests of significance were two-sided. P-
values <0.05 were considered statistically signifi-
cant except in interaction analyses where P-values
<0.20 were considered significant. Data were
analysed using spss 11.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
Results
The mean serum tHcy concentration was
10.8 lmol L)1 (SD 3.3), median was 10.3 lmol L)1.
The subjects were divided into thirds based on the
serum tHcy concentrations. Table 1 presents selected
characteristics of the subjects in the highest serum
tHcy third, in the two lower thirds and in the whole
study population. The men in the highest third
(>11.3 lmol L)1) were significantly older, had lower
serum total cholesterol concentration and higher
systolic blood pressure and smoked less than men in
the lower thirds.
During an average follow-up time of 10.8 years
(8700 person-years of follow-up) 50 men free of
CHD and stroke at baseline experienced a CVD
death. The RR for CVD mortality was 1.72 (95% CI:
Table 1 Characteristics of the
study population at baseline Serum total homocysteine concentration
(lmol L)1)
P*£9.5 9.5–11.3 >11.3
No. of subjects 267 269 266
Serum tHcy (lmol L)1) 8.3 (0.9) 10.4 (0.5) 13.7 (4.2) <0.001
Age (years) 54.2 (6.4) 55.3 (6.6) 56.4 (6.6) <0.001
Serum total cholesterol (mmol L)1) 5.50 (0.92) 5.64 (0.90) 5.41 (0.88) 0.041
Serum LDL cholesterol (mmol L)1) 3.89 (0.82) 4.04 (0.82) 3.84 (0.78) 0.108
Serum HDL cholesterol (mmol L)1) 1.13 (0.29) 1.13 (0.27) 1.10 (0.30) 0.081
Serum triglycerides (mmol L)1) 1.55 (0.96) 1.55 (1.15) 1.61 (0.99) 0.548
Systolic blood pressure (mmHg) 134 (17) 135 (16) 137 (17) 0.029
Body mass index (kg m)2) 27.3 (3.6) 27.5 (3.5) 27.5 (3.5) 0.725
Alcohol intake (g week)1) 81.2 (108.8) 72.6 (93.2) 82.7 (120.6) 0.528
Serum apo-B (g L)1) 0.96 (0.26) 0.97 (0.23) 0.95 (0.24) 0.506
Plasma fibrinogen (g L)1) 3.13 (0.59) 3.12 (0.54) 3.11 (0.57) 0.662
Current smoker (%) 31.1 26.8 22.6 0.041
Diabetes (%) 5.2 7.8 4.9 0.329
Family history of ischaemic
heart disease (%)
50.6 51.7 48.9 0.501
Values are given as mean (SD) or proportions.
*P for highest vs. lower two-thirds
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0.98–3.01, P for trend 0.113) in men in the highest
homocysteine third versus lower thirds after adjust-
ing for age and examination year in the whole
population. After additional adjustments for smo-
king, serum LDL cholesterol and systolic blood
pressure the RR was 1.80 (95% CI: 1.02–3.19, P
for trend 0.097).
The effect of increased serum tHcy concentration
on CVD mortality risk was then studied separately in
men with and without other risk factor present
(Table 2). Increased serum tHcy (>11.3 lmol L)1)
was associated with an age-, examination year- and
systolic blood pressure-adjusted RR for CVD mortal-
ity of 2.25 (95% CI: 1.10–4.59) in men with
increased plasma fibrinogen, 1.93 (95% CI: 0.93–
3.97) increased serum total cholesterol, 2.21 (95%
CI: 1.05–4.62) increased serum LDL cholesterol,
1.91 (95% CI: 0.94–3.86) increased serum apo-B,
and 2.80 (95% CI: 1.12–6.99) amongst smokers. No
Table 2 The age-, examination year- and systolic blood pressure-
adjusted hazard rate ratios (RR) in the highest tHcy third








£3.0 g L)1 0.87 (0.32–2.34) 0.769 18 (4.3)
>3.0 g L)1 2.25 (1.10–4.59) 0.052 32 (8.3)
Serum total cholesterol
£5.5 mmol L)1 1.49 (0.61–3.65) 0.600 20 (5.0)
>5.5 mmol L)1 1.93 (0.93–3.97) 0.139 30 (7.4)
Serum LDL cholesterol
£3.9 mmol L)1 1.05 (0.43–2.56) 0.737 21 (5.3)
>3.9 mmol L)1 2.21 (1.05–4.62) 0.043 29 (7.2)
Serum Apo-B
£0.93 g L)1 1.47 (0.57–3.75) 0.443 18 (4.4)
>0.93 g L)1 1.91 (0.94–3.86) 0.211 32 (8.1)
Smoker
No 1.35 (0.66–2.76) 0.987 31 (5.3)
Yes 2.80 (1.12–6.99) 0.009 19 (8.8)










(% in group)RR (95% CI) P RR (95% CI) P
Fib (g L)1)
1 £11.3 £3.0 1 1 12 (4.3)
2 £11.3 >3.0 1.20 (0.55–2.62) 0.647 1.13 (0.52–2.47) 0.766 14 (5.4)
3 >11.3 £3.0 0.92 (0.34–2.47) 0.870 0.95 (0.35–2.53) 0.814 6 (4.3)
4 >11.3 >3.0 2.96 (1.39–6.29) 0.005 2.48 (1.16–5.34) 0.020 18 (13.8)
Chol (mmol L)1)
1 £11.3 £5.5 1 1 10 (3.9)
2 £11.3 >5.5 1.51 (0.68–3.32) 0.310 1.52 (0.69–3.34) 0.302 16 (5.7)
3 >11.3 £5.5 1.58 (0.65–3.81) 0.311 1.45 (0.60–3.51) 0.409 10 (6.9)
4 >11.3 >5.5 2.95 (1.30–6.68) 0.009 2.94 (1.30–6.65) 0.010 11 (11.3)
LDL (mmol L)1)
1 £11.3 £3.9 1 1 12 (4.6)
2 £11.3 >3.9 1.08 (0.50–2.34) 0.842 1.01 (0.46–2.19) 0.986 14 (5.1)
3 >11.3 £3.9 1.27 (0.53–3.02) 0.594 1.10 (0.46–2.65) 0.829 9 (6.5)
4 >11.3 >3.9 2.41 (1.11–5.21) 0.026 2.33 (1.08–5.05) 0.032 15 (11.5)
Apo-B (mg dL)1)
1 £11.3 £0.93 1 1 9 (3.4)
2 £11.3 >0.93 1.98 (0.88–4.44) 0.099 1.77 (0.79–3.98) 0.169 17 (6.4)
3 >11.3 £0.93 1.71 (0.68–4.33) 0.255 1.53 (0.60–3.89) 0.710 9 (6.3)
4 >11.3 >0.93 3.58 (1.57–8.26) 0.003 3.25 (1.41–7.50) 0.006 15 (11.8)
Smoker
1 £11.3 No 1 1 17 (4.5)
2 £11.3 Yes 1.47 (0.65–3.32) 0.352 1.58 (0.70–3.58) 0.276 9 (5.8)
3 >11.3 No 1.35 (0.66–2.75) 0.412 1.28 (0.63–2.61) 0.499 14 (6.7)
4 >11.3 Yes 4.53 (2.06–9.95) <0.001 4.69 (2.13–10.33) <0.001 10 (16.7)
Hazard rate ratios with 95% confidence intervals and P values are presented using patients with neither high tHcy nor other risk factor
(group 1) as the reference group.
Fib, plasma fibrinogen; Chol, serum total cholesterol.
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association between elevated serum tHcy and CVD
mortality was observed amongst men without these
risk factors (Table 2). The age-, examination year-
and systolic blood pressure-adjusted P value for the
interaction between tHcy and fibrinogen was 0.163,
between tHcy and total cholesterol 0.619, between
tHcy and LDL cholesterol 0.201, between tHcy
and apo-B 0.759 and between tHcy and smoking
0.149.
In Table 3 are presented the RRs for subjects with
both risk factors (increased serum tHcy and either
increased serum total or LDL cholesterol or apo-B,
plasma fibrinogen, or smoking), isolated risk factor
or neither risk factor. The age- and examination
year-adjusted risk of CVD death was significantly
increased in subjects with both increased serum
tHcy and either increased plasma fibrinogen, serum
total cholesterol, serum apo-B or who were smokers
compared with subjects with neither risk factor.
Additional adjustment for systolic blood pressure
only slightly attenuated the associations, except in
smokers where the risk was slightly increased.
Figure 1 presents the age-, examination year- and
systolic blood pressure-adjusted survival curves for
tHcy in the whole population (Fig. 1a) and for the
homocysteine-fibrinogen group (Fig. 1b).
Discussion
The results of this study suggest that high serum
tHcy concentration may increase the risk of CVD
mortality in middle-aged men from Eastern Finland
and especially in men with other prevalent CVD risk
factors, i.e. who are smokers or having high
circulating concentrations of serum total or LDL
cholesterol, apo-B apolipoprotein or plasma fibrin-
ogen. There are a few limitations in our study. First,
the follow-up period was relatively short, so we had
a limited number of outcome events, reducing the
power of the study. We cannot exclude the possibil-
ity that the result that high serum tHcy concentra-
tion is a risk factor for CVD mortality in men with
other heart disease risk factors was confounded by
other factors associated with increased risk of CVD
death. Due to the small number of events, it was not
possible to include multiple covariates in the models.
Secondly, the long storage time of the serum
samples at )20 C, which could potentially weaken
the reliability of serum determinations. However, it
has been shown that long storage time of serum
homocysteine samples does not apparently lead to
alterations in homocysteine concentrations [3]. In
addition, all serum samples underwent the same
freeze–thaw history and were analysed within a
short period of time. The analytical variation in our
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Fig. 1 Age, examination year, smoking, serum LDL cholesterol
and systolic blood pressure-adjusted survival curves for total
homocysteine (tHcy) alone (a) and age-, examination year-
and systolic blood pressure-adjusted survival curves for tHcy-
fibrinogen by group (b).
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The finding of this study that elevated serum tHcy
is a risk factor for CVD mortality is compatible with
some of the previous cohort studies, which have
studied the risk of CVD death in both men and
women [18–20].
However, the main finding in this study was that
increased serum tHcy levels appeared to increase the
risk of CVD mortality in subjects with other CVD risk
factors, although the interaction between tHcy and
other risk factor was considered statistically signifi-
cant only in case of high serum tHcy with high
plasma fibrinogen (P value for the interaction
term ¼ 0.163) or high serum tHcy and smoking
(P ¼ 0.149) [21]. The P value for the interaction
term between tHcy and serum LDL did not quite
reach significance (P ¼ 0.201).
Hypercholesterolaemia [22], increased fibrinogen
[9, 23], and apo-B lipoprotein [12] concentrations,
and smoking [24] are all well-known risk factors for
CVD mortality. There are previous studies where
increased tHcy concentration has been observed to
be an independent risk factor for coronary artery
disease when other risk factors pre-exist. In one
study carried out in hypercholesterolaemic subjects
the risk of an atherosclerotic event in the highest
plasma tHcy fifth was 2.8 times higher when
compared with the lowest fifth [7]. In addition,
72% of the hypercholesterolaemic subjects with
high plasma tHcy concentrations had sustained an
atherosclerotic vascular event, whilst in the hyper-
cholesterolaemic group without increased tHcy
concentrations the occurrence was only 44% [7].
Another study carried out in subjects with elevated
LDL cholesterol concentrations found that even
mildly increased plasma tHcy levels were of crucial
importance for deterioration of endothelial function
[8]. Hypercholesterolaemia has been shown to
impair stimulated endothelium-dependent vasodila-
tation and there is also some evidence that hype-
rhomocysteinemia is associated with arterial
endothelial dysfunction [5, 25, 26]. Increased risk
of mortality in the subjects with both elevated
cholesterol and tHcy concentrations may be
explained by deterioration of endothelial function,
which has been recently demonstrated [27]. The
fact that apo-B is a protein component of
LDL may give an explanation to the observation
that homocysteine is also a risk factor for CVD
mortality in men with elevated plasma apo-B
concentrations.
Similar findings to those found in hypercholes-
terolaemic patients have also been reported in case
of increased plasma fibrinogen levels. Acevedo
et al. [9] reported that although no significant
interaction was demonstrated between fibrinogen
and homocysteine, increased plasma tHcy provided
an additive contribution to the risk of elevated
fibrinogen concentrations. Compared with the
subjects who had neither high fibrinogen nor tHcy
concentrations, patients with increased fibrinogen
had a 2.3 times and subjects with both increased
fibrinogen and tHcy a 3.3 times the risk of
coronary artery disease mortality. The difference
in this study compared with our study is that it
included both men and women, and also patients
with prevalent coronary artery disease (56% of
study population); 76% of the cases had a known
coronary artery disease. The follow-up time was
also shorter (30 ± 14 months). The high risk
observed in this study may partly be a result of
the inclusion of subjects with prevalent CHD or
due to relatively short follow-up time. However,
the increased risk with increased fibrinogen and
tHcy concentrations could be explained by their
complementary roles in the platelet activation-
aggregation cascade. Fibrinogen represents a major
step in platelet aggregation, whilst homocysteine
impairs nitric oxide production and also contri-
butes to the generation of oxidized species
[1, 6, 28].
The observation that elevated serum tHcy con-
centration appeared to increase the risk of CVD
mortality in smoking men is similar to a recent
European Concerted Action Project case–control
study, where smokers were at increased risk of
vascular disease and the risk was greatly increased
in the presence of a raised plasma tHcy concentra-
tion when compared with nonsmokers [10]. In
previous studies cigarette smoking has been shown
to be associated with increased plasma tHcy levels
[10, 11], but in our study population this is not
seen.
Although the mean serum tHcy concentrations
have been similar to the other studies in the Finnish
studies [2–4], severe or moderate hyperhomocyste-
inemia is relatively uncommon in Finland. In our
study only 11 subjects (1.4%) had serum tHcy
values more than 20 lmol L)1. The null findings
in another Finnish study were suggested to be due
to low prevalence of mutations predisposing to
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hyperhomocysteinemia in the Finnish population
[3]. Indeed, homocystinuria is one of the hereditary
disorders that are rare in Finland [29]. Furthermore,
in our study population the prevalence of homozy-
gotes for the methylenetetrahydrofolate reductase
(MTHFR) C677T mutation was found to be 5.3%, if
men with prior CHD were not excluded from the
analyses (S. Voutilainen and J.K. Virtanen, unpub-
lished data). This is somewhat lower than what has
been reported in other studies (10–48%) [30, 31].
An alternative explanation for the findings of this
study could be that homocysteine is just a marker
for CVD. This would be a likely option, especially if
the ongoing folic acid supplementation trials fail to
show any beneficial effect on the risk of CVD despite
decreased blood tHcy levels. If this is the case, then
the increased risk observed when high blood tHcy
concentration is present with other CVD risk factors
could represent an overall deterioration of vascular
health.
In conclusion, high serum tHcy may increase the
risk of CVD mortality in middle-aged men from
Eastern Finland, and it may especially increase the
risk when present with other CVD risk factors,
although in this study the number of CVD deaths is
too low to draw any definite conclusions. If the
results of this study can be confirmed in other
prospective cohort studies, then treatment for
increased homocysteine concentrations should
also be considered in addition to treatments for the
other risk factors in the high-risk populations.
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